Paroxysmal nocturnal hemoglobinuria, or PNH, is a rare, acquired blood disorder where red blood cells break apart too early. This breakdown, called hemolysis, releases hemoglobin into the bloodstream. The condition gets its name from the dark urine people sometimes notice, which is more likely to appear in the morning after sleep. PNH is not inherited, and it is not a form of cancer, though it is closely linked to bone marrow failure conditions.
What Is PNH a Rare Blood Disorder Explained by Its Cause?
PNH begins with a genetic change in a bone marrow stem cell. This change happens during a person’s lifetime, not at conception. The altered stem cell produces blood cells that lack two important surface proteins called GPI-anchored proteins.
Normally, these proteins protect red blood cells from being destroyed by part of the immune system called complement. Without the protective proteins, red blood cells become vulnerable. Complement attacks and destroys them, leading to the hallmark symptoms of PNH.
The specific genes involved are called PIGA genes. When the PIGA gene mutates in a stem cell, the cell cannot make the protective proteins. However, having the mutation alone is not enough. Most people with PIGA mutations never develop PNH. The condition typically appears alongside bone marrow disorders such as aplastic anemia.
What Are the Main Symptoms of PNH?
Symptoms vary widely between patients. Some people have mild symptoms for years. Others experience severe complications quickly. The three main features of PNH are hemolytic anemia, blood clots, and bone marrow failure.
Dark or red urine is the most recognizable symptom, but not everyone gets it. Fatigue is nearly universal because chronic anemia leaves the body short on oxygen-carrying red blood cells. Other common symptoms include shortness of breath, difficulty swallowing, abdominal pain, and erectile dysfunction in men.
Blood clots are the most dangerous complication. They can form in unusual places like the veins of the liver, abdomen, or brain. Clots in the liver veins, called Budd-Chiari syndrome, are particularly associated with PNH. Blood clots are the leading cause of death from this disease.
How Is PNH Diagnosed?
Diagnosis requires a specific blood test called flow cytometry. This test measures whether red and white blood cells have the protective GPI-anchored proteins on their surface. If a significant portion of cells lack these proteins, PNH is confirmed.
Flow cytometry is highly accurate and can detect even small populations of abnormal cells. The test also helps determine the size of the PNH clone, which is the percentage of abnormal blood cells. A larger clone generally means a higher risk of symptoms and complications.
Doctors may suspect PNH when a patient has unexplained anemia, blood clots in unusual locations, or a diagnosis of aplastic anemia. Because symptoms overlap with many other conditions, diagnosis is sometimes delayed. One study found the average time from symptom onset to diagnosis was over a year, though this varies.
What Treatments Are Available for PNH?
Treatment has changed dramatically in the past two decades. Before the 2000s, the only options were supportive care and bone marrow transplantation. Today, most patients can manage the disease effectively with medication.
Eculizumab and ravulizumab are the main drug therapies. These are monoclonal antibodies that block the complement system from destroying red blood cells. They reduce hemolysis, improve anemia, and significantly lower the risk of blood clots. Most patients on these drugs see their dark urine resolve and their fatigue improve substantially.
These medications are given by intravenous infusion. Eculizumab is typically given every two weeks after an initial loading period. Ravulizumab lasts longer in the body and is given every eight weeks. Both drugs are expensive and require ongoing use, but they have transformed PNH from a life-threatening disease into a manageable chronic condition.
Bone marrow transplantation remains the only cure for PNH. However, it carries serious risks including graft-versus-host disease and death from the procedure itself. For this reason, transplantation is usually reserved for patients with severe bone marrow failure or those who do not respond to complement inhibitors.
How Does PNH Affect Life Expectancy?
Before complement inhibitor therapy, PNH was a serious disease with high mortality. Blood clots and bone marrow failure were the main causes of death. Many patients died within 10 to 15 years of diagnosis.
With modern treatment, the outlook is much better. Patients on complement inhibitors have survival rates close to the general population, according to long-term registry data. The risk of blood clots drops dramatically, and quality of life improves significantly.
Still, PNH requires lifelong management. Patients need regular monitoring of blood counts, kidney function, and signs of complications. Some patients develop iron deficiency from chronic hemoglobin loss in urine. Others develop iron overload if they require frequent blood transfusions.
Can PNH Turn Into Other Conditions?
PNH is closely related to aplastic anemia and myelodysplastic syndromes. These are all bone marrow failure disorders, and patients can move between them over time.
Some patients with aplastic anemia develop PNH clones as their bone marrow recovers. Conversely, some PNH patients develop worsening bone marrow failure. The relationship between these conditions is complex and not fully understood.
A small percentage of PNH patients may develop acute myeloid leukemia, a type of blood cancer. This risk is low but real, which is why regular blood monitoring is essential. The leukemia risk is thought to come from the underlying bone marrow instability rather than the PNH clone itself.
Is PNH Hereditary or Contagious?
PNH is not hereditary. Parents cannot pass it to their children. The genetic mutation occurs in a single stem cell during a person’s lifetime, long after birth.
PNH is not contagious either. It cannot spread from person to person through contact, blood transfusion, or any other route. The disease is entirely acquired, meaning it develops within an individual’s own body.
This distinction matters for patients and families. There is no need for genetic testing of relatives. There is also no way to prevent the disease through lifestyle changes. PNH develops due to a random genetic event combined with bone marrow stress, neither of which is under personal control.
What Is It Like Living With PNH Today?
Living with PNH requires adapting to regular medical care. Infusion visits every few weeks become part of the routine. Blood tests track disease activity and treatment response.
Most patients on complement inhibitors lead full, active lives. Fatigue improves but may not completely resolve. Some patients still experience breakthrough hemolysis during infections or stress, which can cause temporary symptom flare-ups.
Support groups and patient advocacy organizations provide valuable resources. Connecting with others who understand the disease helps many patients cope with the emotional burden. PNH is rare, so finding local support can be difficult, but online communities fill this gap.
Frequently Asked Questions
What is the life expectancy for someone with PNH?
With modern complement inhibitor treatment, survival approaches that of the general population. Without treatment, the disease carries a significantly shortened life expectancy due to blood clot risk.
Is PNH a form of cancer?
PNH is not cancer, though it is a blood disorder with some features that overlap with blood cancers. A small percentage of patients can develop leukemia, but this is not the same as having cancer at diagnosis.
Can PNH go into remission on its own?
Spontaneous remission is rare but has been reported in a small number of patients. Most patients require ongoing treatment to control hemolysis and prevent complications.
Does everyone with PNH need treatment?
Not everyone requires immediate treatment. Patients with very small PNH clones and no symptoms may be monitored without medication. Anyone with significant hemolysis, blood clots, or fatigue should discuss treatment with a hematologist.
